Chronic Kidney Disease and Metabolic Disorders in the Elderly

The goal of this observational study is to investigate the impact of metabolic comorbidities on outcomes in elderly Chinese adults, through two parallel sub-cohorts: one comprising elderly individuals without chronic kidney disease (CKD) at baseline, and one comprising elderly patients with established CKD. The main questions it aims to answer are: Do metabolic diseases (diabetes, hypertension, hyperlipidemia, hyperuricemia, calcium-phosphorus disorders) increase the risk of incident CKD, major adverse cardiovascular events (MACE), and all-cause mortality in elderly individuals without CKD at baseline? What are the optimal diagnostic thresholds and criteria for CKD in the elderly population? How do metabolic comorbidities affect long-term outcomes - including all-cause mortality, end-stage renal disease (ESRD), and cardiovascular events - in elderly patients with established CKD? What is the comorbidity profile and disease burden of elderly CKD patients in China? Participants in both sub-cohorts will: Undergo baseline assessments including laboratory tests and clinical evaluations. Provide longitudinal follow-up data through scheduled clinic visits and medical record linkage. Contribute to a large-scale cohort of 100,000 elderly participants across multiple centers in China.

NCT Number	NCT07494526
Lead Sponsor	Chinese PLA General Hospital Collaborators: Fudan University, Beijing Chao Yang Hospital, The First Affiliated Hospital of Dalian Medical University, Beijing Luhe Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Shandong Provincial Hospital, Second Xiangya Hospital of Central South University, Tianjin Medical University
Conditions	Chronic Kidney Diease, Diabetes Mellitus, Hypertension, Hyperlipidemia, Hyperuricemia
Enrollment	100,000 participants
Start Date	2026-04
Primary Completion	2028-12 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-03-27